Skip to main content
Erschienen in: Medical Oncology 4/2008

01.12.2008 | Original Paper

Expression of VEGF and microvessel density in patients with multiple myeloma: clinical and prognostic significance

verfasst von: Olivera Marković, D. Marisavljević, V. Čemerikić, A. Vidović, M. Peruničić, M. Todorović, I. Elezović, M. Čolović

Erschienen in: Medical Oncology | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

The conflicting data are reported on the clinical significance of VEGF deregulation and intensity of angiogenesis in multiple myeloma. The aim of this study was to evaluate the incidence and prognostic significance of VEGF expression and microvessel density (MVD) in multiple myeloma, as well as the relationship of their expression with selected clinical data, histological features, and proliferative activity of myeloma cells. We analyzed bone marrow biopsy specimens obtained from 59 patients with newly diagnosed multiple myeloma. Expression of VEGF and MVD was analyzed using standard immunohistochemical method (antibodies against VEGF and CD34, respectively) on B5-fixed and routinely processed paraffin-embedded bone marrow specimens. MVD was estimated by counting the number of microvessels in three “hot spots” at 400× magnification. VEGF immunoreactivity was estimated on the basis of intensity and percentage of positive plasma cells. VEGF was expressed in 47/59 (79.7%) specimens. There was no significant correlation between VEGF overexpression and age, clinical stage, the extent of osteolytic lesions, type of monoclonal protein, hemoglobin concentration, platelet count, serum concentration of creatinine, calcium, and albumins, the extent of bone marrow infiltration, histological grade, and proliferative activity index (measured with Ki-67 immunoreactivity). No significant difference was observed regarding the overall survival between VEGF-positive and VEGF-negative patients (29 vs. 34 months, P = 0.8). Median MVD was 15, ranging from 1 to 89 microvessels per three “hot spots”. There was significant correlation between MVD and histological grade, the extent of bone marrow infiltration, and proliferative activity. Significant difference was observed regarding the overall survival between patients with low MVD (<15) and patients with high MVD (≥15) (46 vs. 22 months, P = 0.009; univariate analysis). The results of this study did not reveal clinical significance of VEGF overexpression in multiple myeloma. On the contrary, the extent of bone marrow angiogenesis is an indicator of biological potency of malignant clone and a predictor of poor survival in newly diagnosed myeloma.
Literatur
2.
Zurück zum Zitat Hallek M, Bergsagel Pl, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91(1):3–21.PubMed Hallek M, Bergsagel Pl, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91(1):3–21.PubMed
3.
Zurück zum Zitat Folkman J. Tumor angiogenesis. In: Mendelshon J, Howley PM, Israel MA, Liotta LA, editors. The molecular basis of cancer. Philadelphia: W.B. Saunders; 1995. p. 206–32. Folkman J. Tumor angiogenesis. In: Mendelshon J, Howley PM, Israel MA, Liotta LA, editors. The molecular basis of cancer. Philadelphia: W.B. Saunders; 1995. p. 206–32.
4.
Zurück zum Zitat Rajkumar VS, Mesa R, Fonseca R, Shroeder G, Plevak M, Dispenzieri A, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002;8(7):2210–16.PubMed Rajkumar VS, Mesa R, Fonseca R, Shroeder G, Plevak M, Dispenzieri A, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002;8(7):2210–16.PubMed
5.
Zurück zum Zitat Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia. 2006;20(2):193–9.PubMedCrossRef Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia. 2006;20(2):193–9.PubMedCrossRef
6.
Zurück zum Zitat Rajkumar VS, Leong T, Roche P, Fonseca R, Dispenzieri A, Lacy QM, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000;6(3):3111–6.PubMed Rajkumar VS, Leong T, Roche P, Fonseca R, Dispenzieri A, Lacy QM, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000;6(3):3111–6.PubMed
7.
Zurück zum Zitat Sezer O, Niemoller K, Eucker J, Jakob C, Kaufmann O, Zavrski I, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol. 2001;79(10):574–7.CrossRef Sezer O, Niemoller K, Eucker J, Jakob C, Kaufmann O, Zavrski I, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol. 2001;79(10):574–7.CrossRef
8.
Zurück zum Zitat Pruneri G, Ponzoni M, Ferreri A, Decarli N, Tresoldi M, Raggi F, et al. Microvessel density, a surrogate marcer of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Hematol. 2002;118(3):817–20.CrossRef Pruneri G, Ponzoni M, Ferreri A, Decarli N, Tresoldi M, Raggi F, et al. Microvessel density, a surrogate marcer of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Hematol. 2002;118(3):817–20.CrossRef
9.
Zurück zum Zitat Podar K, Anderson K. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implication. Blood. 2005;105(4):1383–95.PubMedCrossRef Podar K, Anderson K. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implication. Blood. 2005;105(4):1383–95.PubMedCrossRef
10.
Zurück zum Zitat Chronic Leukemia-Myeloma Task Force. Guidelines for protocol studies. Cancer Chemother Rep. 1973;4:145–53. Chronic Leukemia-Myeloma Task Force. Guidelines for protocol studies. Cancer Chemother Rep. 1973;4:145–53.
11.
Zurück zum Zitat Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Cancer. 1875;36:842–54.CrossRef Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Cancer. 1875;36:842–54.CrossRef
12.
Zurück zum Zitat Sailer M, Vykoupil KF, Peest D, Coldewey R, Deicher H, Georgii A. Prognostic relevance of a histologic classification system applied in bone marrow biopsies from patients with multiple myeloma: a histopathological evaluation of biopsies from 153 untreated patients. Eur J Haematol. 1995;54:137–46.PubMedCrossRef Sailer M, Vykoupil KF, Peest D, Coldewey R, Deicher H, Georgii A. Prognostic relevance of a histologic classification system applied in bone marrow biopsies from patients with multiple myeloma: a histopathological evaluation of biopsies from 153 untreated patients. Eur J Haematol. 1995;54:137–46.PubMedCrossRef
13.
Zurück zum Zitat Bartl R, Frisch B, Burkhardt R, Fateh-Moghadam AF, Mahl G, Gierster P, et al. Bone marow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. Br J Haematol. 1982;51:361–75.PubMedCrossRef Bartl R, Frisch B, Burkhardt R, Fateh-Moghadam AF, Mahl G, Gierster P, et al. Bone marow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. Br J Haematol. 1982;51:361–75.PubMedCrossRef
14.
Zurück zum Zitat Remmele W, Stenger HE. Vorschlag zur einheitlichen definition eines immunoreactiven score (IRS) fuer den immunohistochemischen oestrogenrezeptor-nachweis (ER-ICA) im mammakarzinomgewebe. Pathologe. 1987;8(3):138–40.PubMed Remmele W, Stenger HE. Vorschlag zur einheitlichen definition eines immunoreactiven score (IRS) fuer den immunohistochemischen oestrogenrezeptor-nachweis (ER-ICA) im mammakarzinomgewebe. Pathologe. 1987;8(3):138–40.PubMed
15.
Zurück zum Zitat Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1–8.PubMed Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1–8.PubMed
16.
Zurück zum Zitat Lai MD, Medeiros LJ, Wilson CS, Sun NC, Koo C, McCourty A, et al. Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf−1, and Ki-67 in multiple myeloma: correlation with cyclin-D1 immunoreactivity. Mod Pathol. 1998;11(7):642–7.PubMed Lai MD, Medeiros LJ, Wilson CS, Sun NC, Koo C, McCourty A, et al. Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf−1, and Ki-67 in multiple myeloma: correlation with cyclin-D1 immunoreactivity. Mod Pathol. 1998;11(7):642–7.PubMed
17.
Zurück zum Zitat Vacca A, Ria R, Ribatti D, Semeraro F, Djonov V, Raimondo F, et al. A paracrine loop in the vascular ebnothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica. 2003;88(2):176–85.PubMed Vacca A, Ria R, Ribatti D, Semeraro F, Djonov V, Raimondo F, et al. A paracrine loop in the vascular ebnothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica. 2003;88(2):176–85.PubMed
18.
Zurück zum Zitat Choi JH, Ahn MJ, Jang SJ, Park CK, Park YW, Oh HS, et al. Absence of clinical prognostic value of vascular endothelial growth factor and microvessel density in multiple myeloma. Int J Hematol. 2002;76(5):460–4.PubMedCrossRef Choi JH, Ahn MJ, Jang SJ, Park CK, Park YW, Oh HS, et al. Absence of clinical prognostic value of vascular endothelial growth factor and microvessel density in multiple myeloma. Int J Hematol. 2002;76(5):460–4.PubMedCrossRef
19.
Zurück zum Zitat Bellamy WT. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol. 2001;28(6):551–9.PubMedCrossRef Bellamy WT. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol. 2001;28(6):551–9.PubMedCrossRef
20.
Zurück zum Zitat Xu JL, Lai R, Kinoshita T, Nakashima N, Nagasaka T. Proliferation, apoptosis, and intramural vascularitis in multiple myeloma: correlation with the clinical stage and cytological stage and cytological grade. J Clin Pathol. 2002;55(7):530–4.PubMed Xu JL, Lai R, Kinoshita T, Nakashima N, Nagasaka T. Proliferation, apoptosis, and intramural vascularitis in multiple myeloma: correlation with the clinical stage and cytological stage and cytological grade. J Clin Pathol. 2002;55(7):530–4.PubMed
21.
Zurück zum Zitat Ribas C, Colleoni GVB, Silva MR, Carregoza MJ, Bordin JO. Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma. Eur J Haematol. 2004;73(5):311–7.PubMedCrossRef Ribas C, Colleoni GVB, Silva MR, Carregoza MJ, Bordin JO. Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma. Eur J Haematol. 2004;73(5):311–7.PubMedCrossRef
22.
Zurück zum Zitat Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, et al. Expression of VEGF and its receptors by myeloma cells. Leukemia. 2003;17(10):2025–31.PubMedCrossRef Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, et al. Expression of VEGF and its receptors by myeloma cells. Leukemia. 2003;17(10):2025–31.PubMedCrossRef
23.
Zurück zum Zitat Kumar S, Witzig TE, Thompson MA, Haug J, Timm T, Wellik L, et al. Expression of angiogenic cytokines by plasma cells: a comparison of MGUS, smoldering myeloma and newly diagnosed symptomatic myeloma. Blood. 2002;100:807a (abstract). Kumar S, Witzig TE, Thompson MA, Haug J, Timm T, Wellik L, et al. Expression of angiogenic cytokines by plasma cells: a comparison of MGUS, smoldering myeloma and newly diagnosed symptomatic myeloma. Blood. 2002;100:807a (abstract).
24.
Zurück zum Zitat Uneda S, Matsuno F, Sonoki T, Tniguchi I, Kawano F, Hata H. Expression of vascular endothelial growth factor and angiopoietin-2 in myeloma cells. Hematologica. 2003;88(1):113–5. Uneda S, Matsuno F, Sonoki T, Tniguchi I, Kawano F, Hata H. Expression of vascular endothelial growth factor and angiopoietin-2 in myeloma cells. Hematologica. 2003;88(1):113–5.
25.
Zurück zum Zitat Usnarska-Zubkiewicz L, Mazur G, Wrobel T, Poreba M, Kuliczowski K. Expression of serum vascular endothelial growth factor correlates with clinical outcome in multiple myeloma. Pol Arch Med Wewn. 2003;110(1):719–22.PubMed Usnarska-Zubkiewicz L, Mazur G, Wrobel T, Poreba M, Kuliczowski K. Expression of serum vascular endothelial growth factor correlates with clinical outcome in multiple myeloma. Pol Arch Med Wewn. 2003;110(1):719–22.PubMed
26.
Zurück zum Zitat Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem. 2001;47:617–23.PubMed Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem. 2001;47:617–23.PubMed
27.
Zurück zum Zitat Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer. 1999;81:1398–401.PubMedCrossRef Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer. 1999;81:1398–401.PubMedCrossRef
28.
Zurück zum Zitat Bhatti SS, Kumar L, Dinda AK, Dawar R. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological and laboratory parameters. Am J Hematol. 2006;81(9):649–56.PubMedCrossRef Bhatti SS, Kumar L, Dinda AK, Dawar R. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological and laboratory parameters. Am J Hematol. 2006;81(9):649–56.PubMedCrossRef
29.
Zurück zum Zitat Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Wellik LA, Fonseca R, et al. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant. 2004;34:235–9.PubMedCrossRef Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Wellik LA, Fonseca R, et al. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant. 2004;34:235–9.PubMedCrossRef
30.
Zurück zum Zitat Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestrias F, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994;87(3):503–8.PubMedCrossRef Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestrias F, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994;87(3):503–8.PubMedCrossRef
31.
Zurück zum Zitat Alexandrakis MG, Passam FH, Dambaki C, Pappa CA, Stathopoulus E. The relationship between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma. J Clin Pathol. 2004;57:856–860.PubMedCrossRef Alexandrakis MG, Passam FH, Dambaki C, Pappa CA, Stathopoulus E. The relationship between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma. J Clin Pathol. 2004;57:856–860.PubMedCrossRef
32.
Zurück zum Zitat Dankbar B, Padro T, Leo R, Feldman B, Kropff M, Mesters RM, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2000;95(8):428–35. Dankbar B, Padro T, Leo R, Feldman B, Kropff M, Mesters RM, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2000;95(8):428–35.
33.
Zurück zum Zitat Podar K, Tzu Tai Y, Davies FE, Lenzsch S, Sattler M, Hideshima T, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98(2):428–35.PubMedCrossRef Podar K, Tzu Tai Y, Davies FE, Lenzsch S, Sattler M, Hideshima T, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98(2):428–35.PubMedCrossRef
34.
Zurück zum Zitat Ahn MJ, Park CK, Choi J, Lee WM, Choi Y, Kim IS, et al. Clinical significance of microvessel density in multiple myeloma patients. J Korean Med Sci. 2001;16(1):45–50.PubMed Ahn MJ, Park CK, Choi J, Lee WM, Choi Y, Kim IS, et al. Clinical significance of microvessel density in multiple myeloma patients. J Korean Med Sci. 2001;16(1):45–50.PubMed
35.
Zurück zum Zitat Du W, Hattori Y, Hashiguchi A, Kondoh K, Hozumi N, Sakamoto M, et al. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment. Pathol Int. 2004;54(5):285–94.PubMedCrossRef Du W, Hattori Y, Hashiguchi A, Kondoh K, Hozumi N, Sakamoto M, et al. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment. Pathol Int. 2004;54(5):285–94.PubMedCrossRef
Metadaten
Titel
Expression of VEGF and microvessel density in patients with multiple myeloma: clinical and prognostic significance
verfasst von
Olivera Marković
D. Marisavljević
V. Čemerikić
A. Vidović
M. Peruničić
M. Todorović
I. Elezović
M. Čolović
Publikationsdatum
01.12.2008
Verlag
Humana Press Inc
Erschienen in
Medical Oncology / Ausgabe 4/2008
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-008-9066-y

Weitere Artikel der Ausgabe 4/2008

Medical Oncology 4/2008 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.